Illumina’s TSO Comprehensive IVD test and two companion diagnostic (CDx) indications secured approval from the FDA last year.

Illumina has launched a new benchtop next-generation sequencing (NGS) system designed to be more accessible for use in smaller labs. NGS is a high-throughput approach to DNA sequencing that has ...

the global NGS market size was valued at $9.19 billion in 2023 and is projected to hit $66.04 billion by 2033, at a CAGR of 21.8%. Year to date, shares of Illumina have plunged 19.1% compared with ...

In an attempt to expand its next-generation sequencing (NGS) platform in the rapidly emerging markets of China, Illumina, Inc.ILMN recently entered into a strategic collaboration with its Chinese ...

Illumina Inc. ILMN recently announced the launch of Connected Insights -- a new cloud-based software that enables tertiary analysis for clinical next-generation sequencing (NGS) data. Connected ...

DNA sequencer manufacturer Illumina has bought Edico Genome and its Dragen next-generation sequencing and data analysis platform. The terms of the deal were not disclosed. Dragen uses field ...

Illumina today laid out a series of moves, a “strategic roadmap,” intended to expand the use of next-generation sequencing (NGS) to clinical settings that have slowly begun warming up to the ...

bioMérieux and Illumina said today they will partner to launch a next-generation sequencing (NGS) epidemiology solution for epidemiological monitoring of bacterial infections. The solution will ...

The Genomics Core offers a full suite of Illumina Next Generation Sequencing library prep services for both DNA and RNA projects for the Illumina platforms. We also accept pre-made libraries for ...

Putting aside the fact that NGS has been around for more than 10 years and is no longer "next generation" but current generation, the bulls largely have it right; Illumina effectively has a firm ...